Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Completed 3Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 78Stomach Neoplasms 14Neoplasms 8Neoplasm Metastasis 8HER2-positive Breast Cancer 4Esophageal Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Brain Neoplasms 4Inflammatory Breast Neoplasms 3Breast Neoplasms, Male 3Triple Negative Breast Neoplasms 2Recurrence 2Ovarian Neoplasms 2Cardiotoxicity 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Solid Tumor 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplastic Cells, Circulating 1Myeloproliferative Disorders 1Mycosis Fungoides 1Multiple Myeloma 1Meningeal Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Flow Cytometry 2talactoferrin alfa 1perifosine 1cabozantinib 1antineoplaston AS 2-1 1antineoplaston A10 1alovudine 1alectinib 1Vorinostat 1Trastuzumab 1Tissue Array Analysis 1Taxes 1Sunitinib 1Reverse Transcriptase Polymerase Chain Reaction 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Polymerase Chain Reaction 1Paclitaxel 1Oxaliplatin 1Oligonucleotide Array Sequence Analysis 1Microarray Analysis 1Mass Spectrometry 1Magnetic Resonance Spectroscopy 1Immunohistochemistry 1Immunoenzyme Techniques 1Gene Expression Profiling 1Fluorodeoxyglucose F18 1Fluorescent Antibody Technique 1Everolimus 1Electroacupuncture 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Salivary Gland Neoplasms × Trastuzumab × Clear all
NCT00126607 2013-02-28

Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
35 enrolled
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡